PDF Solutions (NASDAQ:PDFS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 200 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $27.40 million which beat the analyst consensus estimate of $26.19 million by 4.62 percent. This is a 27.98 percent increase over sales of $21.41 million the same period last year.
Novartis Announced Three-Year Collaboration With Alnylam to Explore Targeted Therapy to Restore Liver Function
Novartis today announced a collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.
